Core Points - Oncolytics Biotech Inc. received a delinquency notification from Nasdaq due to its ordinary shares closing below $1.00 for 30 consecutive business days [1][2] - The company has until August 12, 2025, to regain compliance with the minimum bid price requirement [1][2] - If the bid price reaches or exceeds $1.00 for at least 10 consecutive business days before the deadline, Nasdaq will confirm compliance [2] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an immunotherapeutic agent delivered intravenously [4] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, inducing anti-cancer immune responses [4][5] - The company is conducting combination clinical trials with pelareorep and has received Fast Track designation from the FDA for its studies in metastatic breast cancer and pancreatic cancer [5]

Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that has shown promising results in treating metastatic breast cancer and pancreatic cancer [3][4] - Pelareorep works by inducing anti-cancer immune responses and transforming "cold" tumors into "hot" tumors, enhancing the effectiveness of cancer treatments [3] Leadership Change - Matt Coffey, Ph.D., the President and CEO, will not return after a medical leave of absence and has officially stepped down due to ongoing health concerns [1][2] - Wayne Pisano, Chair of the Board of Directors, will serve as Interim CEO while the company initiates a search for a new CEO [2] Clinical Development - Pelareorep has demonstrated synergies with multiple approved oncology treatments and is currently involved in combination clinical trials for solid malignancies [4] - The company is advancing towards registrational studies for pelareorep in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA [4]

Oncolytics Biotech Inc. (ONCY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individu ...

Core Insights - The 2025 ASCO Gastrointestinal Cancers Symposium is set to highlight the alarming rise in cancer rates among individuals under 50, particularly gastrointestinal cancers, with colorectal and pancreatic cancers being significant concerns [1][2] - Oncolytics Biotech Inc. is presenting data on pelareorep, an innovative immunotherapy that aims to convert "cold" tumors into "hot" tumors, enhancing treatment response [3][4] Company Developments - In a study involving relapsed anal cancer, pelareorep achieved a 33% response rate, with one patient showing a complete response lasting over 15 months, significantly outperforming typical treatment response rates of 10-24% [4][5] - Pelareorep has shown strong potential in pancreatic cancer, with new safety data indicating its compatibility with modified FOLFIRINOX chemotherapy, expanding treatment options for metastatic pancreatic cancer [5][6] - The GOBLET study demonstrated a 62% objective response rate for pelareorep combined with other therapies, more than double the historical average of 25%, leading to its FDA Fast Track designation in 2022 [6][7] Industry Trends - The Global Pancreatic Cancer Treatment Market is projected to grow at a 7.6% CAGR, while the global stomach cancer treatment market is expected to reach $17.6 billion by 2034, growing at a 12.54% CAGR [2] - Other companies presenting at the ASCO GI symposium include Agenus Inc., which will showcase its immunotherapy treatments for colorectal cancer, and ALX Oncology, which is advancing therapies to enhance immune response against cancer [10][11][12]

Core Insights - Oncolytics Biotech's pelareorep shows significant improvement in combination therapy for anal cancer patients compared to checkpoint inhibitors alone [1][2] - The therapy also demonstrates a strong safety profile when combined with a new chemotherapy regimen in pancreatic cancer patients [1][2] Summary by Category Efficacy in Anal Cancer - Pelareorep combined with atezolizumab continues to outperform historical control trials in relapsed anal cancer, with a complete response lasting beyond 12 months [2][4] - In a cohort of 12 evaluable patients, 4 achieved a partial response, resulting in an objective response rate of 33%, which is notably higher than the historical response rates of 10-24% for checkpoint inhibitors alone [4] Safety Profile - No safety concerns have been reported with the pelareorep and atezolizumab combination therapy, indicating a manageable safety profile [4] - Tumor-infiltrating lymphocyte (TIL) clonal expansion was observed in responding patients, suggesting a positive immune response [4] Pancreatic Cancer Developments - Pelareorep has shown promising efficacy signals when combined with gemcitabine, nab-paclitaxel, and atezolizumab in metastatic pancreatic ductal adenocarcinoma (PDAC) [7] - A new cohort in the GOBLET study is evaluating pelareorep with modified FOLFIRINOX, with safety data reviewed positively by regulatory bodies, allowing for continued patient enrollment [7][5] GOBLET Study Overview - The GOBLET study is a phase 1/2 trial exploring treatment combinations with pelareorep in advanced or metastatic gastrointestinal tumors, with co-primary endpoints focusing on objective response rate and safety [10] - The study is being conducted at 17 centers in Germany, with the potential for cohorts meeting efficacy criteria to advance to further stages [11]

Issued on behalf of Oncolytics Biotech Inc. USA News Group News Commentary VANCOUVER, BC, Jan. 15, 2025 /PRNewswire/ -- As 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in cancer research, including cutting-edge AI technologies, novel targeted therapies, and innovative cancer vaccines. With over 50 oncology drug approvals in 2024, including the first tumor-infiltrating lymphocyte cell therapy, this year holds gre ...

New pancreatic cancer cohort moves forward with full enrollment of 30 patients in Stage 1 SAN DIEGO and CALGARY, AB, Jan. 15, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that Germany's medical regulatory body, the Paul-Ehrlich-Institute (PEI), has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with mo ...

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 26, 2024 /PRNewswire/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively tar ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first rec ...

Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approvalAdvancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studiesSAN DIEGO and CALGARY, AB, Dec. 23, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is providing a recap of the major accomplishments from 2024 and a ...